Favipiravir Approved as COVID Drug

Admin

4 years ago

Favipiravir Approved as COVID Drug

Right now, if you will ask someone that name a thing that person wants very badly then that person will say that please give me the vaccine of COVID-19 but no one is able to find the vaccine but some good news is coming in this regard.

Favipiravir:

FabiFlu – Favipiravir produced by Glenmark, has gotten endorsement for the assembling and advertising of the antiviral medication.
Favipiravir is one of the drugs that is being investigated as an expected treatment for Covid-19.
It is the primary medicine to be affirmed and monetarily accessible for the treatment of Covid-19.
It is the primary medicine to be affirmed and monetarily accessible for the treatment of Covid-19.
It was approved way back in 2014.

Will this work in all COVID 19 Cases?

Glenmark has said that the drug is advised for mild to moderate Covid-19 cases.
To address direness of rising Covid-19 cases, Drug Controller General of India optimized consent to Glenmark Pharmaceuticals to fabricate and advertise favipiravir tablets.

Cost:

The drug is priced at Rs. 3,500 for a pack of 34 tablets Rs. 103 per tablet.
It will be available in retail chemist stores and hospitals by next week.

Can you take FabiFlu by yourself?

NO, IT IS A PRESCRIPTION DRUG
Also, Doctors will need a patient’s consent before prescribing the drug.
As per Glenmark, the medication can be utilized in Covid-19 patients with co horrible conditions, for example, diabetes and coronary illness, who have mellow to direct manifestations of the infection.
It offers quick decrease in viral burden inside four days and gives quicker indicative improvement.

How effective is Favipiravir?

Studies from Japan, Russia and China have shown positive results.
Favipiravir shows clinical upgrades of up to 88% in COVID-19, with quick decrease in viral burden by 4 days.
Clinical improvement noted across age bunches 20 to >90 years, remembering for patients with co-grim conditions like diabetes and coronary illness experiencing gentle to direct COVID-19.
Currently, the drug is the subject of at least 18 clinical trials involving more than 3,000 patients across India, USA, Canada, Italy, China, France, UK and other countries.

Are other nations using Favipiravir too?

Favipiravir has so far been endorsed for test use among Covid-19 patients by the controllers of Italy and China.
It was commercially launched in Bangladesh.

How does Favipiravir stop SARS COV2?

The medication works by short circuiting the propagation component of certain RNA infections, for example, flu.
It hinders the activity of “RNA-dependent RNA polymerase (RdRp)” of SARS CoV2.
This prompts the hindering of viral replication and hence diminishes the viral burden and seriousness of the illness.

Is It Fully Tested?

Glenmark has expressed that it’s stage three clinical preliminaries utilizing antiviral medication Favipiravir for Covid-19 patients is demonstrating early encouraging outcomes.
The DCGI has endorsed the medication for limited crisis use, even as the outcomes are yet to be pronounced.
The general stages of the development cycle of a vaccine are:

Exploratory stage
Pre-clinical stage
Clinical development
Regulatory review and approval
Manufacturing
Quality control

Post-Marketing Surveillance Trials:

When a medication enters open use, specialists screen a few thousand volunteers to spot reactions not seen in before preliminaries and to follow how well the immunization functions over expanded time frames.

Are there any risks?
In Japan, Avigan’s utilization has been carefully constrained by the administration because of possible hazard for teratogenicity.
Teratogen = a medication or other substance equipped for meddling with the advancement of a baby, causing birth absconds.
The instrument that makes Avigan successful against infections likewise makes it ruinous to the quick cell development of babies.

Game Changer?

Oral tablets
Easy to administer
Can be taken at home (with a prescription)
Manufactured in India

Which other drugs are in clinical trials in India?

Favipiravir and Umifenovirare the medications affirmed by Drug Controller General of India (DCGI) for clinical preliminaries to treat Covid-19, at Council of Scientific and Industrial Research (CSIR).

Now in clinical trials:

ACQH
Umifenovir (Arbidol)
Mycobacterium W (Anti-Leprosy Drug)

Favipiravir Approved as COVID Drug